

**Supplementary material Table S1. Association of total iron intake and nonheme iron intake with risk of gastric cancer  
stratified by *H. pylori* infection status**

Iron (mg/day)	<i>H. pylori</i> -positive				<i>H. pylori</i> -negative			
	No. of controls (%)	No. of cases (%)	Model I [OR (95% CI)]	Model II [OR (95% CI)]	No. of controls (%)	No. of cases (%)	Model I [OR (95% CI)]	Model II [OR (95% CI)]
<b>Total iron<sup>a</sup></b>								
<i>All</i>								
T1 (<12.04)	170 (36.6)	138 (39.9)	1	1	81 (27.9)	9 (32.1)	1	1
T2 (12.04–14.76)	142 (30.6)	125 (36.1)	1.08 (0.78–1.51)	1.12 (0.77–1.63)	108 (37.2)	13 (46.4)	1.08 (0.44–2.66)	1.20 (0.44–3.33)
T3 (≥14.76)	152 (32.8)	83 (24.0)	0.67 (0.47–0.95)	<b>0.66 (0.44–0.98)</b>	101 (34.8)	6 (21.4)	0.54 (0.18–1.56)	0.40 (0.11–1.47)
p for trend			0.022	<b>0.035</b>			0.217	0.151
<i>Males</i>								
T1 (<11.67)	117 (36.3)	80 (35.1)	1	1	49 (28.2)	5 (31.3)	1	1
T2 (11.67–14.30)	100 (31.1)	94 (41.2)	1.38 (0.92 – 2.05)	1.65 (1.02–2.67)	64 (36.8)	6 (37.4)	0.92 (0.27–3.19)	1.26 (0.29–5.44)
T3 (≥14.30)	105 (32.6)	54 (23.7)	0.75 (0.49 – 1.16)	0.81 (0.48–1.36)	61 (35.0)	5 (31.3)	0.80 (0.22–2.93)	0.70 (0.13–3.74)
p for trend			0.165	0.308			0.738	0.678
<i>Females</i>								
T1 (<12.68)	53 (37.3)	58 (49.2)	1	1	32 (27.6)	5 (41.7)	1	1
T2 (12.68–15.80)	41 (28.9)	30 (25.4)	0.67 (0.37 – 1.22)	0.86 (0.44–1.69)	46 (39.7)	5 (41.7)	0.70 (0.19–2.60)	0.53 (0.10–2.80)
T3 (≥15.80)	48 (33.8)	30 (25.4)	0.57 (0.32 – 1.03)	0.65 (0.34–1.26)	38 (32.7)	2 (16.6)	0.34 (0.06–1.86)	0.47 (0.05–4.29)
p for trend			0.063	0.202			0.206	0.451
<b>Nonheme iron<sup>a</sup></b>								
<i>All</i>								
T1 (<9.10)	170 (36.6)	150 (43.4)	1	1	81 (27.9)	12 (42.9)	1	1
T2 (9.10–11.02)	153 (33.0)	106 (30.6)	0.79 (0.56–1.09)	0.77 (0.53–1.13)	97 (33.5)	9 (32.1)	0.63 (0.25–1.56)	0.58 (0.20–1.68)
T3 (≥11.02)	141 (30.4)	90 (26.0)	0.72 (0.51–1.02)	0.70 (0.47–1.05)	112 (38.6)	7 (25.0)	0.42 (0.16–1.12)	0.28 (0.09–1.94)
p for trend			0.067	0.093			0.088	0.039
<i>Males</i>								
T1 (<8.86)	112 (34.8)	95 (41.7)	1	1	54 (31.0)	4 (25.0)	1	1
T2 (8.86–10.73)	109 (33.9)	73 (32.0)	0.79 (0.53–1.18)	0.70 (0.43–1.13)	56 (32.2)	6 (37.5)	1.45 (0.39–5.41)	1.26 (0.26–6.12)

T3 ( $\geq 10.73$ )	101 (31.4)	60 (26.3)	0.70 (0.46–1.07)	0.67 (0.40–1.12)	64 (36.8)	6 (37.5)	1.27 (0.34–4.72)	1.08 (0.22–5.34)
p for trend			0.099	0.136			0.789	0.948
<b>Females</b>								
T1 ( $< 9.73$ )	56 (39.4)	59 (50.0)	1	1	29 (25.0)	7 (58.3)	1	1
T2 (9.73–11.69)	41 (28.9)	21 (17.8)	0.49 (0.26–0.92)	0.49 (0.24–1.03)	45 (38.8)	3 (25.0)	0.28 (0.07–1.16)	0.25 (0.04–1.51)
T3 ( $\geq 11.69$ )	45 (31.7)	38 (32.2)	0.80 (0.46–1.41)	0.89 (0.46–1.71)	42 (36.2)	2 (16.7)	1.20 (0.04–1.12)	0.26 (0.03–2.05)
p for trend			0.511	0.830			0.057	0.176

<sup>a</sup> The values are presented as tertiles of iron intake.

OR: odds ratio, CI: confidence interval

**Model I:** crude model; **Model II:** adjusted for age, first degree family history of GC, BMI, alcohol consumption, smoking status, education, occupation, monthly income. In the overall subjects, model II was additionally adjusted for gender.

**Supplementary material Table S2. Association of total iron intake and nonheme iron intake with risk of gastric cancer**  
**stratified by smoking status**

Iron (mg/day)	Ever-smoker (current-smoker and ex-smoker)				Non-smoker			
	No. of controls (%)	No. of cases (%)	Model I [OR (95% CI)]	Model II [OR (95% CI)]	No. of controls (%)	No. of cases (%)	Model I [OR (95% CI)]	Model II [OR (95% CI)]
<b>Total iron<sup>a</sup></b>								
<i>All</i>								
T1 (<12.04)	152 (37.0)	90 (40.0)	1	1	99 (28.9)	57 (38.3)	1	1
T2 (12.04–14.76)	137 (33.3)	94 (41.8)	1.16 (0.80–1.68)	1.37 (0.86–2.18)	113 (32.9)	44 (29.5)	0.68 (0.42–1.09)	0.95 (0.54–1.67)
T3 (≥14.76)	122 (29.7)	41 (18.2)	0.57 (0.37–0.88)	<b>0.51 (0.29–0.88)</b>	131 (38.2)	48 (32.2)	0.64 (0.40–1.01)	0.76 (0.44–1.32)
p for trend			0.012	<b>0.016</b>			0.075	0.223
<i>Males</i>								
T1 (<11.67)	131 (32.8)	76 (36.0)	1	1	35 (36.5)	9 (27.3)	1	1
T2 (11.67–14.30)	133 (33.3)	85 (40.3)	1.10 (0.74–1.63)	1.35 (0.83–2.21)	31 (32.3)	15 (45.4)	1.88 (0.72–4.90)	18.81 (2.93–121.0)
T3 (≥14.30)	136 (34.0)	50 (23.7)	0.63 (0.41–0.97)	0.59 (0.35–1.01)	30 (31.3)	9 (27.3)	1.17 (0.41–3.32)	3.52 (0.64–121.7)
p for trend			0.029	0.035			0.870	0.529
<i>Females</i>								
T1 (<12.68)	4 (33.7)	8 (57.1)	1	1	81 (32.8)	55 (47.4)	1	1
T2 (12.68–15.80)	4 (33.7)	4 (28.6)	0.50 (0.08–3.13)	-	83 (33.6)	31 (26.7)	0.55 (0.32–0.94)	0.79 (0.42–1.48)
T3 (≥15.80)	3 (27.3)	2 (14.3)	0.33 (0.04–2.88)	-	83 (33.6)	30 (25.9)	0.53 (0.31–0.91)	0.59 (0.31–1.10)
P for trend			0.299	-			0.024	0.100
<b>Nonheme iron<sup>a</sup></b>								
<i>All</i>								
T1 (<9.10)	154 (37.5)	107 (47.6)	1	1	97 (28.3)	55 (36.9)	1	1
T2 (9.10–11.02)	140 (34.1)	70 (31.1)	0.72 (0.49–1.05)	0.62 (0.39–1.00)	110 (32.1)	45 (30.2)	0.72 (0.45–1.17)	0.91 (0.50–1.60)
T3 (≥11.02)	117 (28.4)	48 (21.3)	0.59 (0.30–0.90)	<b>0.54 (0.32–0.91)</b>	136 (39.7)	49 (32.9)	0.64 (0.40–1.01)	0.76 (0.43–1.33)
p for trend			0.012	<b>0.018</b>			0.068	0.215
<i>Males</i>								
T1 (<8.86)	133 (33.3)	87 (41.2)	1	1	33 (34.4)	12 (36.4)	1	1
T2 (8.86–10.73)	134 (33.4)	69 (32.7)	0.79 (0.53–1.17)	0.69 (0.42–1.13)	31 (32.3)	10 (30.3)	0.89 (0.34–2.35)	1.79 (0.45–7.05)

T3 ( $\geq 10.73$ )	133 (33.3)	55 (26.1)	0.63 (0.42–0.96)	<b>0.55 (0.33–0.93)</b>	32 (33.3)	11 (33.3)	0.95 (0.37–2.45)	1.20 (0.32–4.59)
p for trend			0.031	<b>0.028</b>			0.923	0.880
<b>Females</b>								
T1 ( $< 9.73$ )	4 (36.4)	11 (78.6)	1	1	81 (32.8)	55 (47.4)	1	1
T2 (9.73–11.69)	6 (54.6)	1 (7.1)	0.06 (0.01–0.67)	-	80 (32.4)	23 (19.8)	0.42 (0.24–0.75)	0.51 (0.26–1.00)
T3 ( $\geq 11.69$ )	1 (9.0)	2 (14.3)	0.73 (0.05–10.39)	-	86 (34.8)	38 (32.8)	0.65 (0.39–1.09)	0.76 (0.41–1.42)
p for trend			0.370	-			0.166	0.470

<sup>a</sup> The values are presented as tertiles of iron intake.

OR: odds ratio, CI: confidence interval

**Model I:** crude model; **Model II:** adjusted for age, first degree family history of GC, alcohol consumption, BMI, education, occupation, monthly income, H. pylori infection. In the overall subjects, model II was additionally adjusted for gender

**Supplementary material Table S3. Association of total iron intake and nonheme iron intake with risk of gastric cancer**  
**stratified by regularly exercise**

Iron (mg/day)	No				Yes			
	No. of controls (%)	No. of cases (%)	Model I [OR (95% CI)]	Model II [OR (95% CI)]	No. of controls (%)	No. of cases (%)	Model I [OR (95% CI)]	Model II [OR (95% CI)]
<b>Total iron<sup>a</sup></b>								
<i>All</i>								
T1 (<12.04)	134 (41.0)	97 (40.6)	1	1	116 (27.4)	50 (37.0)	1	1
T2 (12.04–14.76)	112 (34.3)	89 (37.2)	1.10 (0.75–1.61)	1.33 (0.84–2.11)	136 (32.1)	49 (36.3)	0.84 (0.53–1.33)	0.95 (0.55–1.64)
T3 (≥14.76)	81 (24.8)	53 (22.2)	0.90 (0.59–1.40)	0.82 (0.48–1.37)	172 (40.5)	36 (26.7)	0.49 (0.30–0.79)	<b>0.47 (0.26–0.84)</b>
p for trend			0.665	0.456			0.003	<b>0.008</b>
<i>Males</i>								
T1 (<11.67)	96 (44.9)	52 (35.9)	1	1	69 (24.7)	33 (33.3)	1	1
T2 (11.67–14.30)	67 (31.3)	57 (39.3)	1.57 (0.96–2.56)	2.64 (1.34–5.21)	95 (34.1)	43 (43.4)	0.95 (0.55–1.64)	1.16 (0.60–2.26)
T3 (≥14.30)	51 (23.8)	36 (24.8)	1.30 (0.76–2.25)	1.53 (0.75–3.15)	115 (41.2)	23 (23.3)	0.42 (0.23–0.70)	<b>0.41 (0.20–0.85)</b>
p for trend			0.316	0.305			0.003	<b>0.009</b>
<i>Females</i>								
T1 (<12.68)	40 (35.4)	50 (53.2)	1	1	45 (31.0)	13 (36.1)	1	1
T2 (12.68–15.80)	42 (37.2)	22 (23.4)	0.42 (0.22–0.81)	0.57 (0.26–1.26)	45 (31.0)	13 (36.1)	1.00 (0.42–0.39)	1.39 (0.47–4.11)
T3 (≥15.80)	31 (27.4)	22 (23.4)	0.57 (0.29–1.13)	0.57 (0.25–1.28)	55 (37.9)	10 (27.8)	0.63 (0.25–1.57)	0.77 (0.24–2.40)
p for trend			0.089	0.163			0.297	0.584
<b>Nonheme iron<sup>a</sup></b>								
<i>All</i>								
T1 (<9.10)	140 (42.8)	108 (45.2)	1	1	109 (25.7)	54 (40.0)	1	1
T2 (9.10–11.02)	102 (31.2)	70 (29.3)	0.89 (0.60–1.32)	0.91 (0.57–1.46)	148 (34.9)	45 (33.3)	0.61 (0.39–0.98)	0.55 (0.31–0.97)
T3 (≥11.02)	85 (26.0)	61 (25.5)	0.93 (0.62–1.41)	0.83 (0.50–1.38)	167 (39.4)	36 (66.7)	0.44 (0.27–0.71)	<b>0.45 (0.25–0.81)</b>
p for trend			0.722	0.476			0.001	<b>0.011</b>
<i>Males</i>								
T1 (<8.86)	99 (46.3)	58 (40.0)	1	1	65 (23.3)	41 (41.4)	1	1
T2 (8.86–10.73)	66 (30.8)	47 (32.4)	1.22 (0.74–1.99)	1.30 (0.68–2.47)	99 (35.5)	32 (32.3)	0.51 (0.29–0.90)	0.38 (0.19–0.76)

T3 ( $\geq 10.73$ )	49 (22.9)	40 (27.6)	1.39 (0.82–2.36)	1.46 (0.73–2.89)	115 (41.2)	26 (26.3)	0.36 (0.20–0.64)	<b>0.29 (0.14–0.60)</b>
p for trend			0.214	0.282			<0.001	<b>0.002</b>
<b>Females</b>								
T1 ( $< 9.73$ )	39 (34.1)	53 (56.4)	1	1	46 (31.7)	13 (36.1)	1	1
T2 (9.73–11.69)	40 (35.4)	16 (17.0)	0.29 (0.14–0.60)	0.37 (0.16–0.87)	46 (31.7)	8 (22.2)	0.62 (0.23–1.63)	0.85 (0.26–2.76)
T3 ( $\geq 11.69$ )	34 (30.1)	25 (26.6)	0.54 (0.28–1.05)	0.54 (0.25–1.21)	53 (36.6)	15 (41.7)	1.00 (0.43–2.32)	1.44 (0.48–4.33)
p for trend			0.081	0.153			0.835	0.464

<sup>a</sup> The values are presented as tertiles of iron intake.

OR: odds ratio, CI: confidence interval

**Model I:** crude model; **Model II:** adjusted for age, first degree family history of GC, BMI, alcohol consumption, smoking status, education, occupation, monthly income, *H. pylori* infection. In the overall subjects, model II was additionally adjusted for gender.

**Supplementary material Table S4. Association of total iron intake and nonheme iron intake with risk of gastric cancer  
stratified by first degree family history of GC.**

Iron (mg/day)	No. of controls (%)	No. of cases (%)	Yes		No. of controls (%)	No. of cases (%)	No	
			Model I [OR (95% CI)]	Model II [OR (95% CI)]			Model I [OR (95% CI)]	Model II [OR (95% CI)]
Total iron <sup>a</sup>								
All								
T1 (<12.04)	37 (39.0)	35 (45.5)	1	1	213 (32.4)	112 (37.8)	1	1
T2 (12.04–14.76)	35 (36.8)	25 (32.5)	0.76 (0.38–1.51)	0.97 (0.37–2.54)	214 (32.6)	113 (38.2)	1.00 (0.73–1.39)	1.19 (0.81–1.74)
T3 (≥14.76)	23 (24.2)	17 (22.1)	0.78 (0.36–1.70)	0.82 (0.28–2.41)	230 (35.0)	71 (24.0)	0.59 (0.41–0.83)	<b>0.60 (0.39–0.91)</b>
p for trend			0.518	0.728			0.002	<b>0.011</b>
Males								
T1(<11.67)	27 (38.0)	25 (45.5)	1	1	138 (32.6)	60 (31.9)	1	1
T2 (11.67–14.30)	26 (36.6)	17 (30.9)	0.71 (0.31–1.60)	1.30 (0.38–4.51)	137 (32.4)	83 (44.2)	1.39 (0.93–2.10)	1.87 (1.13–3.08)
T3 (≥14.30)	18 (25.4)	13 (23.6)	0.78 (0.32–1.91)	0.94 (0.25–3.53)	148 (35.0)	45 (23.9)	0.70 (0.45–1.10)	0.74 (0.43–1.28)
p for trend			0.569	0.933			0.074	0.166
Females								
T1 (<12.68)	12 (50.0)	10 (45.5)	1	1	73 (31.2)	53 (49.1)	1	1
T2 (12.68–15.80)	7 (29.2)	5 (22.7)	0.86 (0.21–3.55)	2.70 (0.24–30.4)	80 (34.2)	30 (27.8)	0.52 (0.30–0.89)	0.74 (0.39–1.42)
T3 (≥15.80)	5 (20.8)	7 (31.8)	1.68 (0.41–6.96)	6.36 (0.45–89.4)	81 (34.6)	25 (23.1)	0.43 (0.24–0.75)	0.51 (0.26–1.00)
p for trend			0.492	0.151			0.004	0.053
Nonheme Iron <sup>a</sup>								
Total								
T1 (<9.10)	42 (44.2)	36 (46.8)	1	1	209 (31.8)	126 (42.6)	1	1
T2 (9.10–11.02)	31 (32.6)	26 (33.8)	0.98 (0.49–1.94)	1.06 (0.42–2.72)	218 (33.2)	88 (29.7)	0.67 (0.48–0.93)	0.72 (0.49–1.07)
T3 (≥11.02)	22 (23.2)	15 (19.4)	0.80 (0.36–1.76)	0.90 (0.29–2.82)	230 (35.0)	82 (27.7)	0.59 (0.42–0.83)	<b>0.61 (0.41–0.91)</b>
p for trend			0.583	0.874			0.003	<b>0.019</b>
Males								
T1 (<8.86)	27 (38.0)	26 (47.3)	1	1	139 (32.9)	73 (38.8)	1	1
T2 (8.86–10.73)	27 (38.0)	18 (32.7)	0.69 (0.31–1.55)	0.73 (0.23–2.32)	137 (32.4)	60 (31.9)	0.83 (0.55–1.26)	0.79 (0.48–1.31)

T3 ( $\geq 10.73$ )	17 (23.9)	11 (20.0)	0.67 (0.27–1.70)	0.82 (0.21–3.31)	147 (34.7)	55 (29.3)	0.71 (0.47–1.08)	0.65 (0.39–1.09)
p for trend			0.375	0.755			0.117	0.107
<b>Females</b>								
T1 ( $< 9.73$ )	12 (50.0)	8 (36.4)	1	1	73 (31.2)	58 (53.7)	1	1
T2 (9.73–11.69)	8 (33.3)	7 (31.8)	1.31 (0.34–5.08)	1.16 (0.09–14.95)	78 (33.3)	17 (15.7)	0.27 (0.15–0.51)	0.37 (0.18–0.77)
T3 ( $\geq 11.69$ )	4 (16.7)	7 (31.8)	2.63 (0.57–12.0)	14.13 (0.71–280.75)	83 (35.5)	33 (30.6)	0.50 (0.29–0.85)	0.63 (0.33–1.21)
p for trend			0.214	0.082			0.023	0.226

<sup>a</sup> The values are presented as tertiles of iron intake.

OR: odds ratio, CI: confidence interval

**Model I:** crude model; **Model II:** adjusted for age, BMI, alcohol consumption, smoking status, education, occupation, monthly income, *H. pylori* infection. In the overall subjects, model II was additionally adjusted for gender.



Supplementary material Table S5. Associations of *TFRC* rs9846149 polymorphism with risk of gastric cancer

rs9846149	Model	Genotype	No (%)		Model I	OR (95% CI)	
			Controls	Cases		Model II	Model III
<b>Total</b>	<b>Recessive</b>	<b>CC/GC</b>	716 (95.0)	358 (95.7)	1	1	1
		<b>GG</b>	38 (5.0)	16 (4.3)	0.84 (0.46–1.53)	0.87 (0.46-1.67)	0.89 (0.45–1.76)
<b>Males</b>	<b>Recessive</b>	<b>CC/GC</b>	471 (95.0)	235 (96.3)	1	1	1
		<b>GG</b>	25 (5.0)	9 (3.7)	0.72 (0.33–1.57)	0.73 (0.31-1.73)	0.70 (0.28–1.75)
<b>Females</b>	<b>Recessive</b>	<b>CC/GC</b>	245 (95.0)	123 (94.6)	1	1	1
		<b>GG</b>	13 (5.0)	7 (5.4)	1.07 (0.42–2.76)	1.35 (0.48-3.77)	1.38 (0.49–4.36)

*C: major allele; G: minor allele*

*CC/GC: dominant phenotypes; GG: recessive phenotypes*

*OR: odds ratio, CI: confidence interval*

**Model I:** crude model; **Model II:** adjusted for age, BMI, first degree family history of GC, smoking status, alcohol consumption, education, occupation, monthly income; **Model III:** additionally adjusted for *Helicobacter pylori* infection. In the overall subjects, models II, and III were additionally adjusted for gender.